🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Energy Sector SEC Filings — April 06, 2026

Across 10 filings in the S&P 500 Energy stream (with some cross-sector context), proxy season kicks off with 7 DEF/DEFA14A filings highlighting annual meetings in May 2026, mixed executive comp performance (e.g., MAA beat Core FFO $8.77 vs $8.74 target but missed SS NOI -1.36% vs -1.15% and 3-yr TSR -1.47% vs 4.07%), and neutral governance updates. Energy pure-plays show divergence: Phillips 66 (PSX) flags severe Q1 2026 MTM losses of $900M across Refining ($350-450M), Marketing ($300-400M), and Renewables ($100-200M) due to commodity spikes and $3B collateral outflow, offset by strong Midstream $550-600M; Cheniere Energy (LNG) and Partners (CQP) signal leadership stability via transitions/appointments effective April-May 2026. Limited YoY/QoQ trends include MAA audit fees -13% to $2.48M and Copper CTL $0.081/unit distribution payable Apr 10; no broad insider selling/buying or M&A. Portfolio-level: Refining volatility pressures margins/debt (PSX net debt $22B, target $17B by 2027), while LNG/governance steady; implications include near-term refining downside risk but May catalysts for comp votes and board refresh.

4 high priority 6 medium 10 total filings
· daily

US Material Events SEC 8-K Filings — April 06, 2026

Across 50 filings from April 6, 2026, a dominant theme is aggressive financing and refinancing activity, with 12 companies securing new credit facilities, note issuances, or securitizations totaling over $7B (e.g., Trinity $447M railcar notes, PacifiCorp $2.55B LC, Brinks $3.85B facility), signaling strong liquidity access amid stable interest rates (avg ~5%). M&A momentum builds in biotech/healthcare, highlighted by Neurocrine Biosciences' $2.9B acquisition of Soleno Therapeutics (34% premium, adding $190M 2025 revenue asset) and smaller deals like Profusa's $30M LOI. Executive transitions dominate (22 instances), with positive appointments (e.g., American Integrity CFO, Exponent President/CFO) outnumbering resignations, but distress signals emerge in retail/jewelry (Charles & Colvard Chapter 11 DIP financing) and microcaps (dilution, forbearances). No broad period-over-period declines noted, but selective metrics show revenue stability (e.g., Neurocrine INGREZZA $2.51B 2025) and dilution risks (Greenpro shares doubled to 17M). Portfolio implication: Favor healthcare M&A targets and financing beneficiaries; monitor distress for short opportunities. Overall sentiment leans positive/neutral (70%), with materiality skewed to high-impact events (avg 8/10).

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 06, 2026

Across 50 SEC filings from Dow Jones 30 constituents and related entities on April 6, 2026, dominant themes include a surge in proxy materials (25+ DEF/DEFA14A filings) signaling peak annual meeting season in May 2026, with votes on directors, compensation, auditors, and equity plans; ongoing M&A and SPAC activity (Clear Channel merger, Inflection Point IPO, Spring Valley combo); leadership transitions (TVA CEO retirement, Veradigm CFO appointment, Cisco/Verizon board shifts); and debt restructurings/amendments (Clear Channel consents, Mativ Ninth Amendment, Honest Co. First Amendment). Period-over-period trends are sparse but highlight improvements like Horace Mann's core earnings up YoY to $195.8M (ROE +300bps to 12.4%), Madison Air operating cash flows +118% YoY to $480M, and Strategic Acquisitions net loss narrowed 67% YoY to $40k, contrasted by revenue drops (Strategic to $0) and cash plunges (-98%). Capital allocation shows shareholder returns (Horace Mann $57M divs/buybacks), equity grants (Oxbridge Re NEOs), and high debt service burdens (Madison Air 68% of cash flows). Positive regulatory tailwinds for digital assets (Evernorth XRP clarity) and fusion tech (Spring Valley) emerge, but risks from merger delays, financial strains (MSP Recovery advances), and control weaknesses (Madison Air) loom. Portfolio implications favor monitoring DJ30 names like JPM (record $185.6B revenue), Verizon/Cisco board changes for governance signals, with alpha in M&A catalysts amid neutral-to-mixed sentiment (60% neutral).

29 high priority 21 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — April 06, 2026

The April 6, 2026, daily digest of 50 SEC filings reveals a proxy season ramp-up with 15+ DEF 14A/DEFA14A filings for May 2026 annual meetings, emphasizing governance enhancements like board declassification (Schwab), exculpation amendments (CenterPoint), and executive comp approvals amid mixed 2025 performance (e.g., MAA Core FFO beat but TSR miss). M&A activity surges in biotech/healthcare, highlighted by Neurocrine Biosciences' $2.9B acquisition of Soleno Therapeutics (adding $190M 2025 revenue from VYKAT XR) and Profusa's $30M LOI for PanOmics assets, alongside deals like Legence's $426.6M Bowers acquisition boosting pro forma revenue to $3.45B. Period-over-period trends show mixed results: revenue declines in AirSculpt (-15.8% YoY to $151.8M FY25), improvements in losses for Strategic Acquisitions (-67% YoY net loss to $40k), and record highs for JPMorgan ($185.6B revenue, 17% ROE). SPAC IPOs proliferate (Inflection Point $253M, Aperture $90M target), while capital raises include shelf registrations (PodcastOne $150M, Ooma) and debt issuances (Atlas $300M convertibles). Leadership transitions (TVA CEO retirement, Agilent CLO resignation, Treasure Global CEO change) signal potential volatility, but positive capital allocation like Middlesex Water's 53-year dividend streak and $506M capex plan (2026-2028) underscores resilience. Overall, bullish M&A catalysts contrast bearish consumer/procedure volume declines, with no widespread insider selling but neutral-to-positive sentiment in 70% of filings.

25 high priority 25 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 06, 2026

Across 50 filings from the S&P 500 Consumer Discretionary stream (with cross-sector influences from financials and REITs impacting retail/auto/entertainment), proxy season dominates with 25+ DEF 14A/DEFA14A filings highlighting board refreshes (e.g., 50% new independents at Principal Financial), auditor ratifications, and stock incentive plan approvals signaling governance strength and capital allocation toward equity comp. M&A/divestiture activity is robust, including Profusa's $30M PanOmics LOI (closing by June 2026), Aptiv's Versigent spin-off (April 1, 2026), Six Flags' sale of 6 parks (April 6, 2026), and Laird Superfood's acquisition showing 24% YoY sales growth to $45.3M with net income turnaround to $1.6M. Where period comparisons exist, trends show revenue growth (avg +20% YoY in 3 cases) but mixed cash positions (e.g., Laird cash down to $0.16M). Leadership changes (e.g., Veradigm permanent CFO, Mawson board overhaul) indicate strategic pivots, while funding deals like PacifiCorp's $2.55B LC and Goldman Sachs indenture support expansion. Portfolio-level, positive sentiment in 12/50 (24%) vs mixed/neutral, with May 2026 overloaded with 20+ annual meetings as key catalysts; actionable theme is governance-driven stability amid M&A for consumer firms.

30 high priority 20 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 06, 2026

Across 49 filings dominated by proxy statements (over 20 DEF14A/DEFA14A/PREM14A for May 2026 AGMs), the S&P 500 Healthcare stream reveals accelerating M&A and clinical momentum amid routine governance, with Neurocrine Biosciences (NBIX) announcing a $2.9B acquisition of Soleno Therapeutics adding $190M 2025 revenue from VYKAT XR. Period-over-period trends show mixed results: Elvictor Group revenue +0.3% YoY but net loss swing to -$175k (EPS -$0.21 from +$0.24), NewtekOne loan originations +40% YoY to 961 units/$391M in Q1 2026, and Biogen flagging $34M Q1 IPR&D expenses (-$0.19 EPS). Biotech highlights include Praxis Precision Medicines' 77% placebo-adjusted seizure reduction in EMBRAVE trial and FDA priority review for relutrigine (PDUFA Sep 27, 2026). Portfolio-level patterns indicate positive capital deployment via acquisitions/deals (NBIX, ProCap, Six Flags divestiture) and stable guidance (NewtekOne Q1 EPS $0.37-0.47), but expense pressures in pharma; healthcare M&A premiums average ~42% (NBIX 34-51%). Actionable now: monitor May AGMs for comp/share approvals, NBIX close in 90 days.

24 high priority 25 medium 49 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 06, 2026

Across 50 DEF 14A proxy statements filed around April 6, 2026, a dominant theme is robust 2025 financial performance in 12 companies with disclosed metrics, averaging ~10% YoY revenue growth (e.g., JPM +record $185.6B, Howmet +11.1% sales, Quest +11.8%), strong ROE/ROTC (JPM 17%/20%, Horace Mann core ROE +300bps to 12.4%), and shareholder returns via buybacks/dividends (Assurant $468.3M returned, Middlesex 53 yrs dividend growth). Board refreshes and diversity are emphasized (Principal 50% women independents, MAA 7/9 independent), with 8 CEO/exec transitions noted as seamless (Core Molding, Alkermes). Mixed sentiments in REITs/apartments (MAA SS NOI -1.36% miss) contrast positive industrials/aerospace, but neutral governance dominates 70% filings. Capital allocation favors returns (Dorman $41M buybacks, Quest $450M repurchases) over aggressive M&A. Implications: Bullish for financials/insurers with payout growth, watch REITs for occupancy trends; portfolio-level margin stability (no widespread compression) supports overweight high-ROE names ahead of May 2026 meetings.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 06, 2026

The IPO Pipeline stream reveals five new or contextual S-1 filings on April 6, 2026, dominated by mixed/neutral sentiments with Legence Corp. as the standout positive amid acquisition-driven growth. Period-over-period trends show stark contrasts: TEN Holdings' core virtual events revenue declined 15.6% YoY to $2.7M (88.2% of total), while physical events grew 33.3% to $0.4M, contrasting Legence's pro forma revenue expansion to $3.45B for 2025 via Bowers acquisition (up from historical $2.55B). High dilution risks proliferate in 20/20 Biolabs (80% conversion discounts on $712K crowdfunding + $70K notes, warrants for 3.5M shares), SPAC regulatory hurdles in Mountain Crest (PRC VIE/CSRC risks), and resale dynamics in LB Pharma. Capital allocation leans toward growth retention (no dividends across filings), with Legence financing $426.6M M&A via $200M debt post-$780M IPO proceeds. Portfolio-level theme: Early-stage biotechs/events face dilution/revenue headwinds, while services M&A signals consolidation; watch S-1 effectiveness for IPO catalysts.

5 high priority 5 total filings
· daily

Global High-Priority Regulatory Events — April 06, 2026

Across 50 filings in the 'Global High Priority Market Events' stream, dominant themes include Indian regulatory disclosures on insolvencies (e.g., Reliance Home Finance CoC meetings, Aban Offshore NCLAT appeal), RBI money market operations showing persistent liquidity absorption (net -₹3.5L Cr to -₹4.5L Cr daily), and US SEC events like high-value M&A (Neurocrine-Soleno $2.9B takeover) and SPAC/IPO filings (Inflection Point $253M IPO, Aperture AC $90M target). Period-over-period trends reveal mixed financials: JPMorgan record $185.6B revenue/17% ROE (up significantly), Strategic Acquisitions net loss narrowed to $40k from $124k YoY with revenue to $0, MAA Core FFO beat ($8.77 vs $8.74 target) but TSR miss (-1.47% vs 4.07%), Madison Air op cash flow +118% YoY to $480M despite $4B debt. Critical developments flag takeovers (Neurocrine premium 34-51%), CEO retirements (TVA Jul 1), and dilutions (Greenpro shares doubled, Sammaan BlackRock stake -2.23%). Portfolio-level patterns show biotech M&A strength, Indian firm insolvency drags, and SPAC risks from PRC exposures; implications favor tactical plays in US biotech/healthcare amid neutral Indian liquidity.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 06, 2026

Across the 8 filings in the Financial Results & Earnings stream, small-cap and micro-cap companies predominantly reported mixed results with revenue growth in standout cases like SolarMax Technology (+296% YoY to $90.982M) and iQSTEL (+11.9% YoY to $316.9M), but widespread margin compression (e.g., SolarMax gross margin -550 bps to 4.6%, iQSTEL Q4 gross margin +72 bps but overall flat), net losses, and cash burn (e.g., STRATEGIC ACQUISITIONS -98% cash to $508, Nutra -90.1% to $3,603). Period-over-period trends show 4/8 companies with YoY revenue growth averaging +82% in winners, but 5/8 with widening or persistent net losses and deteriorating equity positions (e.g., Elvictor swung to -$175k loss, Neolara full asset impairment). Capital allocation leaned toward equity issuances and dividends (iQSTEL stock dividend $500k), with limited buybacks; no major M&A but forward-looking catalysts like Elvictor's nine Q1 2026 crew contracts signal potential turnarounds. Portfolio-level patterns indicate sector-agnostic cash constraints and operational volatility in finance/telecom/solar, implying high-beta opportunities amid Nasdaq compliance risks (SolarMax). Overall materiality skews high (avg 7.4/10), favoring selective longs on growth outliers while shorting cash burners.

8 high priority 8 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 06, 2026

Across 40 filings in the USA Corporate Distress & Bankruptcy stream, outright distress is limited to one Chapter 11 bankruptcy (Charles & Colvard) and signals like DIP financing, forbearance agreements, covenant loosening, and reverse splits in 5 others, but the majority (28/40) involve new/expanded credit facilities, amendments, or notes issuances indicating proactive liquidity management amid potential pressures. No broad YoY/QoQ revenue declines reported, but isolated metrics show growth in acquired assets (e.g., VYKAT XR $190M 2025 revenue, INGREZZA $2.51B 2025) contrasting distress cases; sentiment skews positive/neutral (32/40) due to M&A premiums and financing access. Key themes include biotech M&A (NBIX-SLNO at 34-51% premiums, Profusa LOI), rail/RE securitizations, and covenant relief (e.g., Martin Midstream ICR to 1.65x, leverage to 5.5x). Portfolio-level pattern: 15/40 filings feature credit expansions/amendments (avg commitment +20-50%), signaling sector-wide deleveraging efforts; dilution risks in 4 cases (e.g., Greenpro shares doubled). Implications: Avoid deep distress names, favor M&A targets and strong refinancers; watch May-June catalysts for deal closes amid bankruptcy milestones.

40 high priority 40 total filings
· daily

US Executive Officer Management Changes SEC — April 06, 2026

Across 31 filings on USA executive and director changes from April 6, 2026, the dominant theme is robust C-suite and board refreshment, with 18 new appointments/promotions (9 CFOs, 4 CEOs, 5+ directors) signaling strategic hiring for growth amid AI, energy demand, and profitability inflection points, versus 13 departures/retirements/terminations. Positive sentiment prevails in 35% of cases (11/31), particularly tech/health/energy sectors with hires boasting cap markets, ops, and scaling expertise (e.g., Oracle 20%+ organic revenue growth, Nerdy FY2026 rev guidance $180-190M, EBITDA breakeven). Neutral sentiment in 55% reflects orderly transitions without disagreements, but mixed signals like FuelCell director opposition (3.6M votes against) and sudden terminations (HealthEquity CTO) flag potential governance risks. No broad YoY revenue declines noted, but portfolio-level trend shows margin improvements in 4 cases (Nerdy +1000bps EBITDA margin implied), continuity in large caps (Cheniere seamless Chairman shift), and heightened retention incentives (Heron exec severance enhancements). Market implications include near-term catalysts from retirements (TVA CEO July 1) and M&A closes (Hologic go-private April 7), favoring longs in growth refreshes while monitoring small-cap churn (e.g., Treasure Global, Solo Brands OTC suspension). Overall, bullish for sectors with proven succession (energy/tech) vs. watch utilities/small caps.

31 high priority 31 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 06, 2026

Across 31 SEC filings on USA Board Room Changes from April 6, 2026, there is elevated C-suite and board turnover with 18 appointments/promotions (e.g., 9 CFO roles) and 13 departures/retirements, skewed positive in tech, energy, and insurance sectors amid growth narratives. Key period trends include strong historical performance like Hologic's 65% revenue growth and 241% share price rise under retiring CEO, Oracle's >20% YoY organic revenue growth, and Nerdy's FY2026 guidance of $180-190M revenue with breakeven EBITDA (1,000bps margin expansion from 2025). Neutral sentiment dominates (19/31), but positive tones in 9 filings highlight expertise additions for scaling (e.g., AI-driven firms like DeFi Development Corp.). Critical implications: CFO influx signals financial discipline for expansion in energy (Expand Energy, Murphy USA) and tech (Oracle, Nerdy); CEO retirements at TVA (July 1) and Hologic (April 7 post-LBO) pose succession risks. Portfolio pattern: 7/12 energy/utility filings show leadership continuity for LNG/AI demand, contrasting sporadic director oppositions (e.g., FuelCell's 3.6M votes against). No broad margin compression but isolated incentives (Broadwind STIP payouts) amid capex reinvestment.

31 high priority 31 total filings
· daily

US Merger & Acquisition SEC Filings — April 06, 2026

The 11 filings reveal a surge in SPAC M&A pipeline activity, with two fresh IPOs (Inflection Point VI at $253M and QDRO at $200M, totaling $453M in new trusts) alongside extensions, updates, and delays in de-SPAC processes, signaling robust blank-check hunting amid favorable redemption dynamics. Completed takeovers dominate high-materiality events: Howmet's $1.8B aerospace acquisition, ProCap's AI-finance bolt-on adding $30B assets and thousands of users, Vireo's cannabis expansion to 10 states with 160+ dispensaries and 12M deliveries, and SWK's merger into RWAY involving $173.5M cash + 6.33M shares issued. Positive sentiment prevails in 4/11 filings (IPAC VI, Horizon, ProCap, Howmet, Vireo), contrasting neutral/mixed tones in SPAC delays and a low-materiality resignation. No explicit YoY/QoQ financial trends disclosed across filings, but capital deployed into trusts/deals highlights liquidity for M&A; SWK delisting and trust amendments indicate maturing SPAC lifecycle risks. Portfolio implication: Elevated US M&A momentum in SPACs, aerospace, fintech, and cannabis, with arbitrage ops in redemption premiums and de-SPAC catalysts through Q2 2026.

11 high priority 11 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 06, 2026

Overnight SEC filings reveal a proxy-heavy stream dominated by DEF 14A/DEFA14A for upcoming May 2026 AGMs across financials (JPM, SCHW, GNW), REITs (MAA), and others, signaling routine governance but with positive comp tweaks (CNP exculpation). Biotech M&A surges with Neurocrine-Soleno $2.9B deal (51% premium, VYKAT XR $190M 2025 rev) and Profusa-Bio Insights $30M LOI, alongside strategic reviews (Playtika) and mergers (Clear Channel). Period trends mixed: Airsculpt rev -15.8% YoY to $151.8M (cases -15.6%), JPM record $185.6B rev/20% ROTCE, Laird Superfood acquiree +24% sales; aggregate 4/10 filings show rev declines avg -15%, offset by loss narrowing (Strategic Acquisitions net loss -67% YoY). Financing active with shelves (PodcastOne $150M, Ooma), SPAC IPOs (Inflection Point $253M), notes (Atlas $300M), but risks from going concerns (PodcastOne) and impairments (Airsculpt $4.6M). Capital allocation favors M&A/debt repayment over buybacks/dividends; insider activity limited but equity grants (Oxbridge NEOs). Key implications: Biotech/health catalysts near-term, monitor aesthetics weakness and SPAC dilutions.

21 high priority 23 medium 44 total filings
· daily

New Federal Contractors — April 04, 2026

This digest covers one civilian NASA contract totaling $181,839,613 in obligations, with zero defense-related awards. The Leland Stanford Junior University received the award from NASA's Goddard Space Flight Center for the Solar Dynamics Observatory Project Heliospheric and Magnetic Imager (HMI) investigation, a 25-year definitive cost-no-fee R&D effort in space science/applications (PSC AR22). The neutral signal (strength 4/10, materiality 6/10) highlights a stable long-term commitment but with only $25,928,889 outlayed to date against a base + all options value of $186,336,824. Highest-conviction signal is the low pricing risk and ~$7.3 million annual revenue estimate for Stanford's space R&D. Key watch item: outlay progress and performance toward the 2027-09-30 end date, amid full and open competition history.

1 total filings
· daily

Significant Contract Modifications ($10M+) — April 04, 2026

NASA's $181,839,613 contract modification to The Leland Stanford Junior University represents 100% civilian agency spending (0/1 defense-related), focusing on the Goddard Space Flight Center's Solar Dynamics Observatory Heliospheric and Magnetic Imager (HMI) project. This definitive cost-no-fee award, active since 2002-10-15 through 2027-09-30, highlights long-term commitment to space science R&D under full and open competition. The neutral signal (avg strength 4/10) balances sustained funding against low outlays of $25,928,889 to date and modest annual revenue estimate of ~$7.3M. Highest-conviction signal is the durability of NASA's space applications R&D investments (PSC AR22, NAICS 541710). Key watch item: outlay progress beyond $25,928,889 and execution toward 2027-09-30 amid potential civilian budget shifts.

1 total filings
· daily

Contract Deobligations Alert — April 04, 2026

This Contract Deobligations Alert digest synthesizes one civilian NASA contract totaling $181,839,613 in obligations to The Leland Stanford Junior University, with a 0/1 defense-related split indicating pure civilian exposure. The dominant agency and sector theme is NASA's long-term commitment to space science/applications R&D via the Solar Dynamics Observatory Project Heliospheric and Magnetic Imager (HMI) investigation. The highest-conviction signal is neutral (4/10 strength), reflecting low outlays of $25,928,889 against the $181,839,613 obligation on a 25-year definitive cost-no-fee contract awarded in 2002. A key risk is stalled outlay progress amid the deobligation alert context, with annual revenue estimated at ~$7.3 million but uncertain due to uneven spending. Investors in civilian space R&D should watch performance toward the 2027-09-30 end date for potential funding continuity or cuts.

1 total filings
· daily

Contract Option Exercises — April 04, 2026

NASA's Goddard Space Flight Center exercised options totaling $181,839,613 on a single long-term contract with The Leland Stanford Junior University, representing 100% civilian exposure with zero defense-related activity. This neutral signal (strength 4/10, materiality 6/10) reflects sustained commitment to space science R&D via the Solar Dynamics Observatory Project Heliospheric and Magnetic Imager (HMI) investigation, a definitive cost-no-fee award under full and open competition running through September 30, 2027. Only $25,928,889 has been outlayed to date out of a base + all options value of $186,336,824, implying an estimated annual revenue of ~$7.3 million amid uneven spending. The highest-conviction signal is the low pricing risk from the cost-no-fee structure, providing durability outside CR/NDAA volatility. Key watch item: outlay progress beyond $25.9 million and performance toward the 2027 end date.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — April 04, 2026

A single mega contract totaling $181,839,613 in obligations was analyzed for the period April 04, 2026 to April 04, 2026, representing 100% civilian exposure (0/1 defense-related) dominated by NASA's Goddard Space Flight Center. The Leland Stanford Junior University received this definitive cost-no-fee award in 2002 for the Solar Dynamics Observatory Project Heliospheric and Magnetic Imager (HMI) investigation, spanning 25 years to 2027-09-30 with only $25,928,889 outlayed to date out of a $186,336,824 base + options value. The highest-conviction signal is neutral (4/10 strength, 6/10 materiality), reflecting long-term space R&D stability tempered by slow outlay progress under full and open competition. Dominant sector theme is civilian space science/applications R&D (PSC AR22, NAICS 541710). Key risk/watch item: monitor outlay progression beyond $25,928,889 and performance toward the 2027-09-30 end date amid cost-no-fee structure.

1 total filings